Why Better Therapeutics Are Trading Higher By 51%; Here Are 20 Stocks Moving Premarket
Portfolio Pulse from Lisa Levin
Several stocks are experiencing significant pre-market movements. CytoMed Therapeutics (GDTC) surged 109.2% after a 9% gain on Monday. Better Therapeutics (BTTX) gained 51.1% following FDA approval of its AspyreRx treatment. Crown ElectroKinetics (CRKN) rose 42.2% after a 14% decline on Monday. On the downside, DSS, Inc. (DSS) fell 17.1% after naming a new Chief Investment Officer. Viridian Therapeutics (VRDN) fell 14.4% after announcing trial data, and Iovance Biotherapeutics (IOVA) fell 12.5% after pricing its public offering.
July 11, 2023 | 12:34 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Better Therapeutics shares gained 51.1% in pre-market trading after the FDA approved the company's AspyreRx treatment.
The significant gain in BTTX's stock price is likely due to the FDA approval of its AspyreRx treatment, which is a positive development for the company.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100
POSITIVE IMPACT
Crown ElectroKinetics shares rose 42.2% in pre-market trading after declining around 14% on Monday.
The rise in CRKN's stock price in pre-market trading is likely a market correction following its 14% decline on Monday.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 100
POSITIVE IMPACT
CytoMed Therapeutics shares surged 109.2% in pre-market trading after gaining 9% on Monday.
The significant surge in GDTC's stock price is likely due to positive market sentiment following its 9% gain on Monday.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEGATIVE IMPACT
DSS, Inc. fell 17.1% in pre-market trading after naming Daniel Lew as Chief Investment Officer.
The fall in DSS's stock price is likely due to market uncertainty following the appointment of a new Chief Investment Officer.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 100
NEGATIVE IMPACT
Iovance Biotherapeutics fell 12.5% in pre-market trading after pricing its public offering of 20,000,000 shares at $7.50 per share.
The fall in IOVA's stock price is likely due to market reaction to the pricing of its public offering, which may be perceived as diluting existing shares.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEGATIVE IMPACT
Viridian Therapeutics fell 14.4% in pre-market trading after announcing data from ongoing Phase 1/2 trial.
The fall in VRDN's stock price is likely due to market reaction to the announced trial data.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 100